All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Lupus nephritis (LN) is the most prevalent serious complication of systemic lupus erythematosus (SLE). Given the limitations with existing diagnostic procedures, there’s an urgent need for a reliable biomarker with high predictive value for LN. Li et al.1 recently published an article in Journal of Autoimmunity, identifying and validating novel urinary biomarkers capable of distinguishing active renal involvement in SLE. Below, we summarize their key findings.
Figure 1. Validation of novel urine biomarkers by ELISA*
AR, active renal; AUC, area under the curve; iSLE, inactive systemic lupus erythematosus; ROC, receiver operating characteristic.
*Adapted from Li, et al.1
Key learnings |
|
Subscribe to get the best content related to lupus delivered to your inbox